^
    Back
    Association details:
    Biomarker:NQO1 positive
    Cancer:Breast Cancer
    Drug:beta-lapachone (ARQ 761) (NQO1 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: D – Preclinical
    New
    Source:
    Anticancer Drugs
    Title:

    Cisplatin enhances the anticancer effect of beta-lapachone by upregulating NQO1

    Excerpt:
    Cisplatin increased the sensitivity of the NQO1-positive but not the NQO1-negative MDA-MB-231 cells to beta-lap treatment....cisplatin markedly increases the sensitivity of cancer to beta-lap in vitro and in vivo by upregulating NQO1.
    Secondary therapy:
    cisplatin
    DOI:
    10.1097/CAD.0b013e328330098d